{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:35:52Z","timestamp":1785803752204,"version":"3.56.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Hypophosphatasia (HPP) is a genetic disease caused by loss-of-function mutations in <jats:italic toggle=\"yes\">ALPL<\/jats:italic>, which encodes tissue-nonspecific alkaline phosphatase (ALP). Early diagnosis and treatment of perinatal and infantile HPP are important because of their high mortality rates. Enzyme replacement therapy (ERT) using human recombinant tissue-nonspecific ALP asfotase alfa was introduced in Korea in 2016. We report the first experience of ERT over 6 years for perinatal lethal and infantile HPP in Korea.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The first patient was a 6-week-old Korean boy with a failure to thrive. The second patient was an 8-day-old Korean-Uzbek body with generalized tonic-clonic seizure with cyanosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>HPP was suspected in both patients because of the very low level of ALP activity and rachitic findings on radiographs, and the disease was confirmed by Sanger sequencing of the <jats:italic toggle=\"yes\">ALPL<\/jats:italic> gene.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>The first patient with infantile HPP started ERT at 21 months of age and the second patient with perinatal HPP started ERT at 30 days of age. Both patients received asfotase alfa (2\u2009mg\/kg 3 times per week subcutaneously, adjusted to 3\u2009mg\/kg 3 times per week if required) for 6 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 6 years of ERT, radiographic findings and growth standard deviation scores improved in both patients. The second patient showed no evidence of rickets after 3 years of ERT. Mechanical respiratory support and supplemental oxygen were not required after 4.5 years of treatment in the first patient and at 2 months after treatment in the second patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Among the 2 patients, the patient who started ERT early had a much better prognosis despite a more severe initial clinical presentation. Our results suggest that early diagnosis and prompt treatment play an important role in improving long-term prognosis and avoiding morbidity and premature mortality in patients with perinatal and infantile HPP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032800","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:34:46Z","timestamp":1676046886000},"page":"e32800","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Six-year clinical outcomes of enzyme replacement therapy for perinatal lethal and infantile hypophosphatasia in Korea: Two case reports"],"prefix":"10.1097","volume":"102","author":[{"given":"Insung","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Public Health Administration, Asan City Health Center, Asan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu-Seon","family":"Noh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja-Hyun","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Yeon","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Won","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Orthodontics, The Institute of Oral Health Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-059X","authenticated-orcid":false,"given":"Sung Yoon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","article-title":"Alkaline phosphatase and hypophosphatasia.","volume":"98","author":"Mill\u00e1n","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/jhg.2010.161","article-title":"Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia in Japanese and effects of the mutation on heterozygous carriers.","volume":"56","author":"Watanabe","year":"2011","journal-title":"J Hum Genet"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia.","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20250504","first-page":"302","article-title":"First Korean case of infantile hypophosphatasia with novel mutation in ALPL and literature review.","volume":"46","author":"Park","year":"2016","journal-title":"Ann Clin Lab Sci"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets.","volume":"46","author":"Thacher","year":"2000","journal-title":"J Trop Pediatr"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jbmr.3377","article-title":"Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: the Radiographic Global Impression of Change scale.","volume":"33","author":"Whyte","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5385\/nm.2020.27.1.26","article-title":"Case report of lethal perinatal hypophosphatasia with seizure and respiratory failure diagnosed by ALPL gene muation.","volume":"27","author":"Lee","year":"2020","journal-title":"Neonatal Med"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1297\/cpe.29.9","article-title":"Clinical practice guidelines for hypophosphatasia.","volume":"29","author":"Michigami","year":"2020","journal-title":"Clin Pediatr Endocrinol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia.","volume":"101","author":"Whyte","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/humu.24010","article-title":"Large-scale in vitro functional testing and novel variant scoring via protein modeling provide insights into alkaline phosphatase activity in hypophosphatasia.","volume":"41","author":"Del Angel","year":"2020","journal-title":"Hum Mutat"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pd.859","article-title":"Positive maternal serum triple test screening in severe early onset hypophosphatasia.","volume":"24","author":"Witters","year":"2004","journal-title":"Prenat Diagn"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1297\/cpe.19.7","article-title":"Clinical characteristics of perinatal lethal hypophosphatasia: a report of 6 cases.","volume":"19","author":"Nakamura-Utsunomiya","year":"2010","journal-title":"Clin Pediatr Endocrinol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00431-004-1612-9","article-title":"Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia.","volume":"164","author":"Michigami","year":"2005","journal-title":"Eur J Pediatr"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ymgme.2008.03.015","article-title":"Functional assay of the mutant tissue-nonspecific alkaline phosphatase gene using U2OS osteoblast-like cells.","volume":"94","author":"Orimo","year":"2008","journal-title":"Mol Genet Metab"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"116089","DOI":"10.1016\/j.bone.2021.116089","article-title":"Dental outcomes for children receiving asfotase alfa for hypophosphatasia.","volume":"152","author":"Schroth","year":"2021","journal-title":"Bone"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:01:56Z","timestamp":1746327716000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032800","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}